The container body has a body part including an upper part positioned closer to a neck part, a lower part positioned closer to a bottom part, and a central part positioned between the upper part and the lower part. The body part has an oval shape having a short diameter and a long diameter in a cross section perpendicular to a center axis, and includes a pair of first side surfaces disposed at both ends of the short diameter, and a pair of second side surfaces disposed at both ends of the long diameter. The body part has a pair of buckling prevention parts formed continuously in the center axis direction on the pair of second side surfaces of the central part.
The primary purpose of the present invention is to provide, for albumin deficiency symptoms which requires administration of zinc, a formulation that is capable of further improving the efficiency of zinc replenishment. The secondary purpose of the present invention is to provide a formulation that has a treatment effect for iron overload disorders. In the present invention, a first pharmaceutical composition, for intravenous injection and containing zinc ions and serum albumin, is capable of more efficiently replenishing zinc for albumin deficiency symptoms that requires administration of zinc, and a second composition, for intravenous injection and containing zinc ions, is capable of removing iron in vivo for iron overload disorders.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The present invention addresses the problem of providing an emulsified nutritional composition having excellent emulsion stability and having total calories of 0.9 kcal/mL or greater, where the ratio of lipid calories to total calories is 40% or greater. This emulsified nutritional composition contains protein and lipid, and has total calories of 0.9 kcal/mL or greater, where the ratio of lipid calories to total calories is 40% or greater. The protein contains collagen peptides having a weight-average molecular weight of 3000 or less.
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
The present invention addresses the problem of providing: an excellent agent that has an energy consumption promoting action, suppresses an increase in body weight and body fat percentage, and/or can contribute to prevention or amelioration of obesity; and a pharmaceutical composition or a food composition containing the agent. The problem can be solved by using a compound represented by formula (A).
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
To provide a light guide used to facilitate insertion of a medical tube into a body of a patient.
To provide a light guide used to facilitate insertion of a medical tube into a body of a patient.
[SOLUTION] A light guide to be used for inserting a medical tube into a body for nasogastric tube feeding, the light guide including: a main body part having a long length, the main body part being configured to guide light entering a proximal end part from a light source device, to emit resultant light from a distal end part, wherein the main body part includes a linear part having a predetermined length from the distal end part, and a curved part continuous with the linear part, the curved part having a predetermined curvature radius, the linear part has a length in a range of from 40 mm to 100 mm, and the curved part has a curvature radius in a range from 105 mm to 225 mm
An antiseptic composition with a more extended applicable range by further enhancing the efficacy of olanexidine gluconate, which has been used as a highly safe dermal bactericidal disinfectant, and extending antibacterial spectrum. The antiseptic composition includes olanexidine gluconate and is basic and has a more extended bactericidal spectrum than conventional disinfectants.
METHOD FOR PRODUCING A MICROORGANISM HAVING N-DEACETYLATION ACTIVITY AND N-SULFATION ACTIVITY, METHOD FOR PRODUCING A HEPAROSAN-DERIVED COMPOUND, AND A MICROORGANISM HAVING N-DEACETYLATION ACTIVITY AND N-SULFATION ACTIVITY
The present invention relates to a method for producing a microorganism having N-deacetylation activity and N-sulfation activity, including a step (I) of modifying a nucleotide sequence of a DNA encoding N-deacetylase/N-sulfotransferase, and a step (II) of introducing the DNA containing the nucleotide sequence modified in the step (I) into a microorganism in an expressible manner, wherein the step (I) is a step of performing codon optimization according to the codon usage frequency of a biological species different from the microorganism. Further, the invention relates to a method for producing a microorganism having N-deacetylation activity and N-sulfation activity, including a step (i) of expressing a specific protein in a microorganism.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Infusion solutions; Dietetic foods and beverages adapted for medical use; Health food supplements; Dietary and nutritional supplements; Pharmaceutical preparations for the treatment of obesity; Cell preparations, namely, animal cells for the treatment of diseases and conditions; Living tissues, namely, animal tissues from which cells can be harvested for the treatment of diseases and conditions; Pharmaceutical preparations and substances for the treatment of diabetes; Chemical preparations for medical use, namely, transparent gels for ensuring visual field in endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology; Chemical preparations for medical purposes for use in the field of endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology. Medical light sources and gastroesophageal sterile tubes and catheters; Endoscopy cameras for medical purposes; medical apparatus and instruments for ensuring visual field in endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology. Medical services; Medical information; Medical examination; Medical and pharmaceutical consultation; Dietary and nutritional guidance
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Infusion solutions; Dietetic foods and beverages adapted for medical use; Health food supplements; Dietary and nutritional supplements; Pharmaceutical preparations for the treatment of obesity; Cell preparations, namely, animal cells for the treatment of diseases and conditions; Living tissues, namely, animal tissues from which cells can be harvested for the treatment of diseases and conditions; Pharmaceutical preparations and substances for the treatment of diabetes; Chemical preparations for medical use, namely, transparent gels for ensuring visual field in endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology; Chemical preparations for medical purposes for use in the field of endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology Medical light sources and gastroesophageal sterile tubes and catheters; Endoscopy cameras for medical purposes; medical apparatus and instruments for ensuring visual field in endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology Medical services; Medical information; Medical examination; Medical and pharmaceutical consultation; Dietary and nutritional guidance
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Infusion solutions; Dietetic foods and beverages adapted for medical use; Health food supplements; Dietary and nutritional supplements; Pharmaceutical preparations for the treatment of obesity; Cell preparations, namely, animal cells for the treatment of diseases and conditions; Living tissues, namely, animal tissues from which cells can be harvested for the treatment of diseases and conditions; Pharmaceutical preparations and substances for the treatment of diabetes; Chemical preparations for medical use, namely, transparent gels for ensuring visual field in endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology; Chemical preparations for medical purposes for use in the field of endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology. Medical light sources and gastroesophageal sterile tubes and catheters; Endoscopy cameras for medical purposes; medical apparatus and instruments for ensuring visual field in endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology. Medical services; Medical information; Medical examination; Medical and pharmaceutical consultation; Dietary and nutritional guidance
The object of the present invention is to provide an antiseptic composition that can reduce the risk of an incise drape coming off from the skin, without adversely affecting microbicidal activity, even when the incise drape is affixed to skin surface after application of the antiseptic composition, and/or exerts more effective microbicidal activity. A composition comprising a microbicide and a sugar alcohol is used as the antiseptic composition.
A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
An object of the present invention is to provide a new method for providing nutritional supplementation to a subject in poor nutrition state while preventing or suppressing refeeding syndrome, and an enteral nutrient preparation that can be used in the method. As a means for solving the problem, provided is the enteral nutrient preparation including protein and a lipid, and an amino acid as necessary, in which 90 wt % or more of the protein is not milk-derived protein, and (a) an amino acid score of a mixture of the protein and the amino acid is 100 and a lipid calorie ratio is 40% or more, or (b) an amino acid score of a mixture of the protein and the amino acid is less than 100 and a lipid calorie ratio is 15% or more.
An objective of the present invention is to provide an adhesion preventing material exhibiting an excellent adhesion preventing effect. The adhesion preventing material contains a crosslinked gelatin gel having an uncrosslinked lysine residue number of 1.15×10-4mol/g to 2.50×10-4mol/g.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; lacteal flour for babies; nutritional supplements consisting primarily of proteins, fats and/or carbohydrates in liquid, jelly or gel form; nutritional supplements; dietary supplements for humans.
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
32 - Beers; non-alcoholic beverages
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Jellies for food; jellies, jams, compotes; gelatine for food; meat jellies; fish jellies; fruit jellies; vegetable jellies; kanten [dried pieces of agar jelly]; meat jellies containing collagen peptides; fish jellies containing collagen peptides; fruit jellies containing collagen peptides; vegetable jellies containing collagen peptides; protein milk; soya milk in jelly; soya-based snack foods; milk-based beverages flavored with coffee; milk-based beverages containing fruit juice; fruit-based, vegetable-based, bean-based or nut-based snacks. Puddings; jellies [confectionery]; bavarian creams; confectionery; bread and buns; porridge; processed grains; boxed lunches consisting of rice, with added meat, fish or vegetables; instant confectionery mixes; ice cream mixes; sherbet mixes; coffee; cocoa; tea; sweets; artificial coffee; pastries; processed cereals; preparations made from rice; wheat, processed; ready-to-eat cereals; gluten-free cereal products; cereal bars. Soft drinks; fruit juices; vegetable juices [beverages]; whey beverages; beer; extracts of hops for making beer; fruit and vegetable smoothies; non-alcoholic beverages for nutritional purposes; non-alcoholic beverages; smoothies; energy drinks; isotonic beverages; soft drinks in jelly; fruit juices in jelly; vegetable juices in jelly [beverages]; whey beverages in jelly; isotonic beverages in jelly; concentrates, syrups and powders used in the preparation of soft drinks; syrups and other non-alcoholic preparations for making beverages; powders used in the preparation of non-alcoholic beverages for nutritional purposes; powders used in the preparation of fruit-based beverages; syrups for beverages; soft drinks in powder form; fruit juices in powder form; vegetable juices in powder form [beverages]; whey beverages in powder form; isotonic beverages in powder form; non-alcoholic beverages, other than for dietary or medical purposes; powder used in the preparation of non-alcoholic beverages, other than for dietary or medical purposes; soft drink mixes; non-carbonated soft drinks; coffee-flavored soft drinks; fruit-flavored soft drinks; vitamin fortified soft drinks; sports drinks. Dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; lacteal flour for babies; dietary and nutritional supplements consisting primarily of proteins, fats and/or carbohydrates in liquid, jelly, gel or powder form; dietary and nutritional supplements; dietary supplement drinks; dietary supplement drink mixes; powdered nutritional supplement drink mix.
17.
MEDICAL CAP, MEDICAL CONTAINER, AND PRODUCTION METHOD FOR MEDICAL CONTAINER
This medical cap is provided with: a stopper that is disposed inside a cylindrical mouth part having an opening formed therein; and a case. The case includes: a cylindrical inner wall that is disposed between the stopper and the mouth part in a state of being in contact with the stopper and the mouth part; and a cylindrical outer wall that encloses the inner wall having therebetween a cylindrical space in which the mouth part is accommodated. The inner wall includes thin-wall portions and thick-wall portions that have mutually different thicknesses in the radial direction of the case. The thin-wall portions and the thick-wall portions are arranged side by side in the circumferential direction of the case.
A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
18.
MEDICAL CAP, MEDICAL CONTAINER, AND METHOD FOR MANUFACTURING MEDICAL CAP
A medical cap according to the present invention comprises: a plug disposed inside a cylindrical mouth part that forms an opening; and a case provided with a cylindrical inner wall disposed between the plug and the mouth part, a cylindrical outer wall surrounding the inner wall across a cylindrical space accommodating the mouth part, and a top wall disposed above the mouth part disposed in the cylindrical space. The plug includes an inside section surrounded by the inner wall and a lower section disposed between the top wall and the mouth part disposed in the cylindrical space.
A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
Provided are a liquid agent container formed of a multilayer film using polybutylene terephthalate in an outer layer, in which it is controlled or prevented that a component derived from the polybutylene terephthalate is permeates the multilayer film and is eluted into a content liquid, and a multilayer film for forming such a liquid agent container. A multilayer film includes at least a layer (1) including polybutylene terephthalate, a layer (2) including a cyclic olefin-based polymer, a flexible layer (3) including an ethylene-based resin, and a layer (4) including a polyolefin, which are laminated, wherein the layer (1), the layer (2), and the layer (4) forming one surface of the multilayer film are laminated in this order, and a liquid agent container is formed of the multilayer film so that the layer (4) is formed as the innermost layer.
B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Non-alcoholic beverages for providing and maintaining water and electrolytes in cases of dehydration; non-alcoholic isotonic beverages; sports drinks containing electrolytes; non-alcoholic isotonic gel beverages; non-alcoholic isotonic jelly beverages; powders for making isotonic drinks Electrolyte drinks for medical purposes; dietetic beverages adapted for medical purposes; nutritional supplements; oral rehydration solution for medical purposes; oral rehydration drinks for providing and maintaining water and electrolytes in cases of dehydration; oral rehydration solution for medical purposes in the form of gels; oral rehydration solution for medical purposes in jelly form; powdered nutritional supplement drink mix
The present invention relates to: a carbonated jelly beverage for suppressing water consumption; a carbonated jelly beverage for alleviating thirst; a powder preparation for producing these carbonated jelly beverages; a water consumption suppression method comprising consumption of a carbonated jelly beverage; and a thirst alleviation method comprising consumption of a carbonated jelly beverage.
Problem
Problem
To provide a novel cold medicine or antiviral agent.
Problem
To provide a novel cold medicine or antiviral agent.
Means for Solution
Problem
To provide a novel cold medicine or antiviral agent.
Means for Solution
A cold medicine comprising a compound represented by formula (1) or a pharmaceutically acceptable salt thereof.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
Provided is a means for more efficiently transplant an encapsulated islet. A liquid for preservation or transplantation of an encapsulated islet, said liquid containing trehalose, a derivative thereof or a salt of the same.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietetic beverages adapted for medical purposes; dietetic
foods adapted for medical purposes; beverages for babies;
food for babies; lacteal flour for babies; nutritional
supplements consisting primarily of proteins, fats and/or
carbohydrates in liquid, jelly, gel or powder form;
nutritional supplements; dietary supplements for human
beings; dietary supplements for human beings, namely,
dietary supplement drinks, dietary supplement in liquid,
jelly, gel or powder form, and dietary supplement drink
mixes; nutritional supplements, namely, powdered nutritional
supplement drink mix.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietetic foods adapted for medical purposes; dietetic
beverages adapted for medical purposes; beverages for
babies; food for babies; lacteal flour for babies;
nutritional supplements consisting primarily of proteins,
fats and/or carbohydrates in liquid, jelly, gel or powder
form; nutritional supplements; dietary supplements for
humans; pharmaceutical preparations.
The present invention addresses the problem of providing: a cell cryopreservation liquid which can effectively inhibit mammalian cell death caused by freezing and thawing of the cells and which can effectively increase the proliferation ability of mammalian cells after freezing and thawing; and a cryopreservation method for mammalian cells, in which the cell cryopreservation liquid is used. In the present invention, a liquid comprising 2.5-8.75 (v/v)% propylene glycol is used as a mammalian cell cryopreservation liquid.
The purpose of the present invention is to provide a formulation which is for producing an oil-in-water emulsion composition that has zinc chloride as an active component and which provides excellent separation inhibiting properties and/or drug release properties. Provided is an oil-in-water emulsion composition comprising: (A) not less than 30 mass% of zinc chloride; (B) an oil-based base selected from the group consisting of hydrocarbon oils and higher alcohols; (C) a non-ionic surfactant; and (D) an aqueous base selected from the group consisting of water and polyalcohols. The content of (B) with respect to 100 parts by weight of the component (B) and the component (C) combined is not less than 52 parts by weight. The content of (B) with respect to 100 parts by weight of the component (B) and the component (D) combined is not less than 11.7 parts by weight. Thus, the oil-in-water emulsion composition has excellent separation inhibiting properties. When the component (D) is water and polyethylene glycol, the oil-in-water emulsion composition has excellent drug release properties.
The present invention provides a syringe for cryopreservation, characterized by comprising a barrel having an injection port and an opening, a gasket slidably accommodated in the barrel, a plunger connected to the gasket, and a cap for sealing the injection port of the barrel, wherein the opening of the barrel is sealed only by the gasket. The syringe is excellent in usability, durability, and safety.
Provided are a novel printed base material and the like. In particular, provided is a printed base material comprising a printed area on a base material, wherein the printed area comprises a differently colored printed area having different colors separated by a clearance.
According to the present invention, a syringe is provided for the cryopreservation of cells, nucleic acids, or proteins, the syringe being characterized by comprising: a barrel having a discharge section and an opening, and accommodating cells, nucleic acids, or proteins; a gasket slidably accommodated in the barrel; a plunger connected to the gasket; and a cap that seals the discharge section of the barrel, the barrel being formed from a fluororesin, and the gasket being formed from a fluororesin or a polyethylene resin. This syringe excels in usability, durability, and safety.
A nutritional formulation for use in suppressing a symptom of refeeding syndrome includes a protein and/or an amino acid in a total amount of 3.5 g or less per 100 kcal. A method for providing nutritional support while suppressing symptoms of refeeding syndrome in patients in an undernutrition state includes the use of the nutritional formulation which includes a protein and/or an amino acid in a total amount of 3.5 g or less per 100 kcal.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Provided are an adhesion preventing agent and an adhesion preventing method using the same. Specifically, provided are an adhesion preventing agent, including at least one anionized nanomaterial selected from the group consisting of anionized nanocellulose and anionized nanochitin, and an adhesion preventing method using the adhesion preventing agent.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; pharmaceutical preparation for
children and infants; amino acid preparations;
chemico-pharmaceutical preparations; dietary supplements for
human beings; nutritional supplements; nutritional
supplements for children and infants; dietetic foods adapted
for medical purposes; dietetic beverages adapted for medical
purposes; pharmaceutical preparations and substances for the
treatment of kidney diseases; pharmaceutical preparations
for the treatment of malnutrition; intravenous fluids used
for nutrition being pharmaceuticals; infusion solution being
pharmaceuticals.
The present invention provides an improved encapsulated pancreatic islet. A formulation comprising a core covered with a five-layered membrane, wherein the core comprises one or more pancreatic islets; and the first, third, and fifth membranes from the inner side of the five-layered membrane contain alginic acid, and the second and fourth membranes from the inner side contain polyornithine.
An object of the present invention is to provide a method for efficiently producing heparosan by improving a heparosan-producing ability through genetic modification of a bacterium of the genus Escherichia which has a heparosan-producing ability. The present invention relates to a bacterium of the genus Escherichia which has a genetic modification that increases an expression of a kpsS gene, and which has a heparosan-producing ability; and a method for producing heparosan using the bacterium.
Corynebacterium, which contains a gene encoding an ATP sulfurylase and a gene encoding an APS kinase, which are expressible, and in which a cell plasma membrane of the transformant (a) is substance-permeable, or a treated matter of the transformant (a), and conducting a reaction for producing PAPS by using a reaction solution containing ATP or an ATP source, a sulfate ion source, and the transformant (a) or the treated matter thereof.
Low molecular weight heparin (LMWH) suitable for equivalent use to USP enoxaparin sodium is prepared from a starting material isolated from engineered E. coli K5 capsular polysaccharide, e.g., E. coli K5 heparosan. The E. Coli CPS is treated with acids to remove 3-deoxy-D-manno oct-2-ulosonic acid (Kdo) residues, and further hydrolyzed via alkali treatment to form low molecular weight N-sulfo, N-acetyl heparosan (LMW-NSNAH) having molecular weight and N-acetylation comparable to enoxaparin. The LMW-NSNAH is converted to LMWH via a series of enzymatic modifications by C5-epimerase, 2-O-, 6-O-, and 3-O-sulfotransferases. Compositions including the LMWH are prepared without the use of porcine-derived heparin, and thus benefit from better source material availability, better control of manufacturing processes, reduced concerns about contamination, adulteration or animal virus, or impurities. Further, the LMWH product is demonstrated to be structurally and functionally comparable traditional pharmaceutical LMWHs.
Low molecular weight heparin (LMWH) suitable for equivalent use to USP enoxaparin sodium is prepared from a starting material isolated from engineered E. coli K5 capsular polysaccharide, e.g., E. coli K5 heparosan. The E. Coli CPS is treated with acids to remove 3-deoxy-D-manno oct-2-ulosonic acid (Kdo) residues, and further hydrolyzed via alkali treatment to form low molecular weight N-sulfo, N-acetyl heparosan (LMW-NSNAH) having molecular weight and N-acetylation comparable to enoxaparin. The LMW-NSNAH is converted to LMWH via a series of enzymatic modifications by C5-epimerase, 2-O-, 6-O-, and 3-O-sulfotransferases. Compositions including the LMWH are prepared without the use of porcine-derived heparin, and thus benefit from better source material availability, better control of manufacturing processes, reduced concerns about contamination, adulteration or animal virus, or impurities. Further, the LMWH product is demonstrated to be structurally and functionally comparable traditional pharmaceutical LMWHs.
The present invention addresses the problem of providing a composition that is used in order to prevent or suppress refeeding syndrome. Provided as a solution to the problem is a composition that is used to prevent or suppress refeeding syndrome, the composition containing an mTOR inhibitor.
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
The present invention provides an improved method for producing pancreatic islet-containing capsules.
The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
(a) preparing a sodium alginate solution A containing pancreatic islets at a concentration of 10,000 IEQ/mL or more;
The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
(a) preparing a sodium alginate solution A containing pancreatic islets at a concentration of 10,000 IEQ/mL or more;
(b) adding the sodium alginate solution to a divalent cation solution dropwise, and collecting gelled particles;
The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
(a) preparing a sodium alginate solution A containing pancreatic islets at a concentration of 10,000 IEQ/mL or more;
(b) adding the sodium alginate solution to a divalent cation solution dropwise, and collecting gelled particles;
(c) adding the particles collected in step (b) to a poly-L-ornithine solution A, followed by stirring and then collecting particles;
The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
(a) preparing a sodium alginate solution A containing pancreatic islets at a concentration of 10,000 IEQ/mL or more;
(b) adding the sodium alginate solution to a divalent cation solution dropwise, and collecting gelled particles;
(c) adding the particles collected in step (b) to a poly-L-ornithine solution A, followed by stirring and then collecting particles;
(d) adding the particles collected in step (c) to a sodium alginate solution B, followed by stirring and then collecting particles; and
The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
(a) preparing a sodium alginate solution A containing pancreatic islets at a concentration of 10,000 IEQ/mL or more;
(b) adding the sodium alginate solution to a divalent cation solution dropwise, and collecting gelled particles;
(c) adding the particles collected in step (b) to a poly-L-ornithine solution A, followed by stirring and then collecting particles;
(d) adding the particles collected in step (c) to a sodium alginate solution B, followed by stirring and then collecting particles; and
(e) adding the particles collected in step (d) to a sodium citrate solution, followed by stirring and then collecting particles.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
The object of the present invention is to provide an antiseptic composition that can reduce the risk of an incise drape coming off from the skin, without adversely affecting microbicidal activity, even when the incise drape is affixed to skin surface after application of the antiseptic composition, and/or exerts more effective microbicidal activity. A composition comprising a microbicide and a sugar alcohol is used as the antiseptic composition.
The present invention addresses the problem of providing a disinfecting composition that, when an incise drape is placed on the skin surface on which the disinfecting composition has been applied, can reduce the risk of the incise drape peeling from the skin without detrimentally affecting the bactericidal potency thereof, and/or realize more effective bactericidal potency. The disinfecting composition contains a bactericidal agent and a sugar alcohol.
The present invention addresses the problem of providing: a novel method for supplying nutrients while preventing or suppressing the development of refeeding syndrome in a subject with a nutrient-poor condition; and an enteral nutrient preparation that can be used in the method. As a solution for the problem, an enteral nutrient preparation is provided, which comprises a protein, a lipid, and optionally an amino acid, in which a protein other than a milk-derived protein makes up 90% by weight or more of the protein, and (a) the amino acid score of a mixture of the protein and the amino acid is 100 and the calorific ratio of the lipid is 40% or more or (b) the amino acid score of a mixture of the protein and the amino acid is less than 100 and the calorific ratio of the lipid is 15% or more.
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
[Problem] To provide: a liquid agent container formed from a multilayer film in which polybutylene terephthalate is used in an outer layer, the liquid agent container being such that elution of a component derived from the polybutylene terephthalante into a liquid contained in the liquid agent container through the multilayer film is suppressed or prevented; and a multilayer film for forming such a liquid agent container. [Solution] Provided is a multilayer film obtained by laminating at least (1) a layer that contains polybutylene terephthalate, (2) a layer that contains a cyclic-olefin-based polymer, (3) a flexible layer that contains an ethylene-based resin, and (4) a layer that contains a polyolefin, the multilayer film being such that the layer (1), the layer (2), and the layer (4), which forms one surface of the multilayer film, are laminated in the stated order. Also provided is a liquid agent container formed from the multilayer film such that the layer (4) serves as the innermost layer.
An object of the present invention is to provide a pharmaceutical composition containing mesenchymal stem cells that exhibit excellent therapeutic effects on various diseases, injured parts, wounds and decubitus. The present invention relates to a pharmaceutical composition for treating a non-porcine animal, the pharmaceutical composition includes a neonatal pig-derived mesenchymal stem cell which produces at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A and VEGF-C.
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
48.
TREHALOSE-CONTAINING LIQUID FOR MAMMALIAN CELL PRESERVATION
The present invention addresses the problem of providing, for instance, a mammalian cell preservation solution that can effectively suppress a decrease in cell viability occurring when mammalian cells are preserved in liquid or a decrease in self-renewal potential occurring when mammalian stem cells are preserved in liquid, and that is less likely to cause a harmful effect on the life of a mammal at the time of in vivo administration of mammalian cells to the mammal. This solution involves preserving a mammalian cell by using a mammalian cell preservation solution comprising trehalose or a derivative thereof, or a salt thereof and a hydrogen carbonate, such as sodium bicarbonate, as a pH modifier, and having a pH of from 6.5 to 8.5.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Antiseptics; cleansing preparations for skin and mucous membranes for medical purposes; antiseptic preparations for skin and mucous membranes; antiseptic preparations for surgical sites; antiseptic preparations for use in preventing infection in wounds; antiseptic preparations for medical instruments; antiseptic preparations used for hospital operating rooms and hospital rooms
An object of the present invention is to provide a novel preservation solution for preserving mammalian cells over a long period of time in a non-frozen state. Ascorbic acid and/or niacin is added to an isotonic solution to prepare a preservation solution. The preservation solution is mixed with platelets and preserved under shaking. Decrease in the functions and viability of the platelets can thereby be suppressed for at least 10 days. Alternatively, the aforementioned preservation solution is mixed with mesenchymal stem cells, megakaryocytes, or T cells and preserved in a non-frozen state. Decrease in the functions and viability of these cells can thereby be suppressed for at least several days to several tens of days.
A liquid material including a polysaccharide is manufactured by creating a mixture of polysaccharides and an aqueous solvent or an aqueous cosolvent with organic solvents at a temperature at which gelation does not occur. The mixture is also irradiated at this lower temperature, such as with ultrasound waves in combination with stirring and/or bubbling of inert gases, to apply ultrasound to a mixture of. Compared with conventional reactions with low concentration solutions, the product yield and advantageous mechanical properties are significantly increased. Depolymerization (decomposition, disassembly) of polysaccharide in the liquid material does not occur to any substantial degree, and the molecular structure of the polysaccharide is maintained. Further, the liquid material does not gel even when the temperature is raised, and thus, its fluidity is maintained, despite polysaccharides being maintained at a high concentration. The liquid material is applicable to myriad industries, including pharmaceuticals and health foods.
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
32 - Beers; non-alcoholic beverages
Goods & Services
Dietetic beverages adapted for medical purposes; dietetic
foods adapted for medical purposes; beverages for babies;
food for babies; lacteal flour for babies; dietary and
nutritional supplements consisting primarily of proteins,
fats and/or carbohydrates in liquid, jelly, gel or powder
form; dietary and nutritional supplements; dietary
supplement drinks; dietary supplement drink mixes; powdered
nutritional supplement drink mix. Jellies for food; jellies, jams, compotes; gelatine for
food; meat jellies; fish jellies; fruit jellies; vegetable
jellies; kanten [dried pieces of agar jelly]; meat jellies
containing collagen peptides; fish jellies containing
collagen peptides; fruit jellies containing collagen
peptides; vegetable jellies containing collagen peptides;
protein milk; soya milk in jelly; soya-based snack foods;
milk-based beverages flavored with coffee; milk-based
beverages containing fruit juice; fruit-based,
vegetable-based, bean-based or nut-based snacks. Puddings; jellies [confectionery]; bavarian creams;
confectionery; bread and buns; porridge; processed grains;
boxed lunches consisting of rice, with added meat, fish or
vegetables; instant confectionery mixes; ice cream mixes;
sherbet mixes; coffee; cocoa; tea; sweets; artificial
coffee; pastries; processed cereals; preparations made from
rice; wheat, processed; ready-to-eat cereals; gluten-free
cereal products; cereal bars. Soft drinks; fruit juices; vegetable juices [beverages];
whey beverages; beer; extracts of hops for making beer;
fruit and vegetable smoothies; non-alcoholic beverages for
nutritional purposes; non-alcoholic beverages; smoothies;
energy drinks; isotonic beverages; soft drinks in jelly;
fruit juices in jelly; vegetable juices in jelly
[beverages]; whey beverages in jelly; isotonic beverages in
jelly; concentrates, syrups and powders used in the
preparation of soft drinks; syrups and other non-alcoholic
preparations for making beverages; powders used in the
preparation of non-alcoholic beverages for nutritional
purposes; powders used in the preparation of fruit-based
beverages; syrups for beverages; soft drinks in powder form;
fruit juices in powder form; vegetable juices in powder form
[beverages]; whey beverages in powder form; isotonic
beverages in powder form; non-alcoholic beverages, other
than for dietary or medical purposes; powder used in the
preparation of non-alcoholic beverages, other than for
dietary or medical purposes; soft drink mixes;
non-carbonated soft drinks; coffee-flavored soft drinks;
fruit-flavored soft drinks; vitamin fortified soft drinks;
sports drinks.
53.
MEDICAL TUBE AND MEDICAL TUBE POSITION DETECTION SYSTEM
To provide such a medical tube that a position of a distal end part thereof is easily detectable from an outside of a body of a patient, regardless of orientation of the distal end part inserted into the body. A medical tube including: a main body part having a tubular shape; at least one opening formed in a side face of a main body part; and a light transmitting part formed at one end of the main body part, the light transmitting part having a hemispherical face shape, the light transmitting part being configured to emit light from a light source.
A drug administration device according to the present invention is a drug administration device for subcutaneously administering a drug, and includes a main body portion configured to be arranged on skin of a patient, and a movable portion to which at least one needle member protruding toward the skin is attached. The movable portion is configured to be capable of being moved between a first position that is spaced apart from the skin and a second position that is near the skin. The leading end portion of the needle member is to be inserted into the skin when the movable portion is located at the second position. The drug is to be discharged from a hole provided in the needle member.
Provided is a novel printed substrate. This printed substrate is provided with a printed section disposed on the substrate, wherein the printed section includes a multicolor printed section in which different colors are printed, separate from each other by a clearance.
B05D 1/26 - Processes for applying liquids or other fluent materials performed by applying the liquid or other fluent material from an outlet device in contact with, or almost in contact with, the surface
B05D 5/06 - Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures to obtain multicolour or other optical effects
Provided is a novel printed substrate. This printed substrate is provided with a printed section disposed on the substrate, wherein the printed section includes a multicolor printed section in which different colors are printed, separate from each other by a clearance.
B05D 1/26 - Processes for applying liquids or other fluent materials performed by applying the liquid or other fluent material from an outlet device in contact with, or almost in contact with, the surface
B05D 5/06 - Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures to obtain multicolour or other optical effects
B41M 3/00 - Printing processes to produce particular kinds of printed work, e.g. patterns
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Antiseptic and anti-bacterial ointment; medicated ointments for medical purposes for the treatment of dermatological conditions; medicated skin cleanser; medicated skin moisturizer; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for skin wounds
To provide a novel cold remedy or antiviral agent. A cold remedy including a compound represented by general formula (1) or a pharmaceutically acceptable salt thereof.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
To provide a novel cold remedy or antiviral agent. A cold remedy including a compound represented by general formula (1) or a pharmaceutically acceptable salt thereof.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Provided are: a novel method for performing nutrition supply while suppressing the symptoms of refeeding syndrome in patients in a low nutritional state; and a nutrition formulation which can be used in said method. Provided is a nutrition formulation which contains a protein and/or an amino acid in an amount of at most 3.5 g per 100 kcal in the total amount, and is used for suppressing the symptoms of refeeding syndrome.
The present invention provides an improved encapsulated islet. This encapsulated islet is a preparation in which a core is coated with five layers of films, the core includes an islet, the first, third, and fifth films from the inside among the five layers of films include alginic acid, and the second and fourth films from the inside include polyornithine.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
The present invention provides an improved encapsulated islet. This encapsulated islet is a preparation in which a core is coated with five layers of films, the core includes an islet, the first, third, and fifth films from the inside among the five layers of films include alginic acid, and the second and fourth films from the inside include polyornithine.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
[OBJECT] To provide a light guide used to facilitate insertion of a medical tube into a body of a patient. [SOLUTION] A light guide to be used for inserting a medical tube into a body for nasogastric tube feeding, the light guide including: a main body part having a long length, the main body part being configured to guide light entering a proximal end part from a light source device, to emit resultant light from a distal end part, wherein the main body part includes a linear part having a predetermined length from the distal end part, and a curved part continuous with the linear part, the curved part having a predetermined curvature radius, the linear part has a length in a range of from 40 mm to 100 mm, and the curved part has a curvature radius in a range from 105 mm to 225 mm
The present invention provides an adhesion-preventing agent and a method for preventing adhesion that uses the same. The present invention relates to: an adhesion-preventing agent containing at least one anionized nano ma-terial selected from the group consisting of anionized nanocellulose and anionized nanochitin; and a method for preventing adhesion using the adhesion-preventing agent.
The present invention provides an adhesion-preventing agent and a method for preventing adhesion that uses the same. The present invention relates to: an adhesion-preventing agent containing at least one anionized nano material selected from the group consisting of anionized nanocellulose and anionized nanochitin; and a method for preventing adhesion using the adhesion-preventing agent.
The purpose of the present invention is to provide a viscoelastic composition having excellent operability, which is suitable for use in securing the field of view of an endoscope when opaque dark-colored liquid accumulates inside a canal and obstructs the field of view of the endoscope, the viscoelastic composition securing the field of view by pushing the liquid aside, and to provide a method for securing the field of view of an endoscope using the viscoelastic composition. The viscoelastic composition for securing the field of view of an endoscope comprises a substance having viscoelastic properties and water, preferably has a hardness of 550 N/m2 or less, a viscosity (25° C.) of 200 to 2,000 mPa·s, and a loss tangent of 0.6 or less, and more preferably has an electrical conductivity of 250 μS/cm or less. The method for securing the field of view of an endoscope comprises feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.
An object of the present invention is to provide a substance capable of effectively suppressing the decrease in cell viability and the cell aggregation that occur when mammalian cells are preserved in a liquid, and less likely to adversely affect, when administered in vivo to a mammal, the body of the mammal, and a mammalian cell preservation liquid containing such a substance, and the like. Use of a liquid containing acarbose or a salt thereof and/or stachyose or a salt thereof for preserving a mammalian cell can effectively suppress the decrease in cell viability and the cell aggregation that occur when mammalian cells are preserved in a liquid. Further, the mammalian cell preserved in the liquid can be directly administered in vivo to a mammal, without being transferred into a new transplantation liquid.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietetic beverages adapted for medical purposes; dietetic
foods adapted for medical purposes; beverages for babies;
food for babies; lacteal flour for babies; nutritional
supplements consisting primarily of proteins, fats and/or
carbohydrates in liquid, jelly, gel or powder form;
nutritional supplements; dietary supplements for humans;
dietary supplement drinks; dietary supplement in liquid,
jelly, gel or powder form; dietary supplement drink mixes;
powdered nutritional supplement drink mix.
69.
METHOD FOR PRODUCING HEPAROSAN AND BACTERIUM OF GENUS ESCHERICHIA HAVING HEPAROSAN-PRODUCING ABILITY
An object of the present invention is to provide a method for efficiently producing heparosan by improving a heparosan-producing ability through genetic modification of a bacterium of the genus Escherichia which has a heparosan-producing ability. The present invention relates to a bacterium of the genus Escherichia which has a genetic modification that increases an expression of a kpsS gene, and which has a heparosan-producing ability; and a method for producing heparosan using the bacterium.
An object of the present invention is to provide a method for efficiently producing heparosan by improving a heparosan-producing ability through genetic modification of a bacterium of the genus Escherichia which has a heparosan-producing ability. The present invention relates to a bacterium of the genus Escherichia which has a genetic modification that increases an expression of a kpsS gene, and which has a heparosan-producing ability; and a method for producing heparosan using the bacterium.
An object of the present invention is to provide a method for easily producing sulfated polysaccharides by reacting a PAPS production/regeneration system utilizing the metabolic activity of a microorganism or a treated matter thereof with a microorganism expressing a sulfation enzyme or a treated matter or extract thereof upon mixing of inexpensive raw materials such as magnesium sulfate. Another object of the present invention is to provide a practical method for producing PAPS from inexpensive raw materials. The present invention relates to a method for producing a sulfated polysaccharide and a method for producing PAPS, the methods comprising a step of preparing a transformant (a) of a bacterium of the genus Corynebacterium, which comprises at least a gene encoding an ATP sulfurylase and a gene encoding an APS kinase which are introduced thereinto in an expressible manner, and in which a cell plasma membrane of the transformant (a) is substance-permeable, or a treated matter of the transformant (a); and a step of conducting a reaction for producing PAPS by using a reaction solution containing ATP or an ATP source, a sulfate ion source, and the transformant (a) or the treated matter thereof.
C12P 19/32 - Nucleotides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same-ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
72.
METHOD FOR PRODUCING HEPAROSAN AND BACTERIUM OF GENUS ESCHERICHIA HAVING HEPAROSAN-PRODUCING ABILITY
An object of the present invention is to provide a method for efficiently producing heparosan by improving a heparosan-producing ability through genetic modification of a bacterium of the genus Escherichia which has a heparosan-producing ability. The present invention relates to a bacterium of the genus Escherichia which has a genetic modification that increases an expression of a kpsS gene, and which has a heparosan-producing ability; and a method for producing heparosan using the bacterium.
An object of the present invention is to provide a method for easily producing sulfated polysaccharides by reacting a PAPS production/regeneration system utilizing the metabolic activity of a microorganism or a treated matter thereof with a microorganism expressing a sulfation enzyme or a treated matter or extract thereof upon mixing of inexpensive raw materials such as magnesium sulfate. Another object of the present invention is to provide a practical method for producing PAPS from inexpensive raw materials. The present invention relates to a method for producing a sulfated polysaccharide and a method for producing PAPS, the methods comprising a step of preparing a transformant (a) of a bacterium of the genus Corynebacterium, which comprises at least a gene encoding an ATP sulfurylase and a gene encoding an APS kinase which are introduced thereinto in an expressible manner, and in which a cell plasma membrane of the transformant (a) is substance-permeable, or a treated matter of the transformant (a); and a step of conducting a reaction for producing PAPS by using a reaction solution containing ATP or an ATP source, a sulfate ion source, and the transformant (a) or the treated matter thereof.
C12P 19/32 - Nucleotides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same-ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
74.
METHOD FOR PRODUCING SULFATED POLYSACCHARIDE AND METHOD FOR PRODUCING PAPS
An object of the present invention is to provide a method for easily producing sulfated polysaccharides by reacting a PAPS production/regeneration system utilizing the metabolic activity of a microorganism or a treated matter thereof with a microorganism expressing a sulfation enzyme or a treated matter or extract thereof upon mixing of inexpensive raw materials such as magnesium sulfate. Another object of the present invention is to provide a practical method for producing PAPS from inexpensive raw materials. The present invention relates to a method for producing a sulfated polysaccharide and a method for producing PAPS, the methods comprising a step of preparing a transformant (a) of a bacterium of the genus Corynebacterium, which comprises at least a gene encoding an ATP sulfurylase and a gene encoding an APS kinase which are introduced thereinto in an expressible manner, and in which a cell plasma membrane of the transformant (a) is substance-permeable, or a treated matter of the transformant (a); and a step of conducting a reaction for producing PAPS by using a reaction solution containing ATP or an ATP source, a sulfate ion source, and the transformant (a) or the treated matter thereof.
C12P 19/32 - Nucleotides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same-ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
75.
MAMMALIAN CELL PRESERVATIVE SOLUTION CONTAINING ACARBOSE AND DEXTRAN
The present invention addresses the problem of providing: a substance which can effectively prevent the decrease in cell survival rate which has been conventionally observed when a mammalian cell is preserved in a liquid, and which is less likely to adversely affect a living body of a mammal when the substance is administered to the mammal in vivo; a mammalian cell preservative solution containing the substance; and others. When a solution containing acarbose or a salt thereof and dextran or a salt thereof is used for the preservation of a mammalian cell, it becomes possible to effectively prevent the decrease in cell survival rate which has been conventionally observed when the mammalian cell is preserved in a liquid. A mammalian cell preserved in the solution can be directly administered to a mammal in vivo without requiring the transfer of the mammalian cell into another liquid for transplantation.
A viscoelastic composition for securing the field of view of an endoscope, the viscoelastic composition comprising a thickening substance and water and having a shear storage modulus G′ of 0.7 Pa or more, and a method for securing the field of view of an endoscope, the method comprising feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.
A61B 1/012 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor
77.
CRYSTAL OF AMINO ACID SALT OF 3-HYDROXYISOVALERIC ACID AND PRODUCTION METHOD THEREOF
An object of the present invention is to provide a crystal of an amino acid salt of HMB which is easy to handle and has high solubility, and to provide a method for producing the same. According to the present invention, the crystal of an amino acid salt of HMB can be precipitated by dissolving an amorphous amino acid salt of HMB in a solvent containing alcohol and stirring or allowing the solvent to left stand. In addition, the crystal of an amino acid salt of HMB can be precipitated by concentrating an aqueous HMB solution of an amino acid salt which has a pH of 2.5 to 11.0.
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 51/41 - Preparation of salts of carboxylic acids by conversion of the acids or their salts into salts with the same carboxylic acid part
C07C 59/01 - Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
C07C 51/43 - SeparationPurificationStabilisationUse of additives by change of the physical state, e.g. crystallisation
C07C 277/06 - Purification or separation of guanidine
C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
78.
METHOD FOR PRODUCING PANCREATIC ISLET-CONTAINING CAPSULE
Provided is an improved method for producing a pancreatic islet-containing capsule. This method for producing a pancreatic islet-containing capsule includes: (a) a step for preparing a sodium alginate solution A containing pancreatic islands at a concentration of at least 10,000 IEQ/mL; (b) a step for dropping the sodium alginate solution into a divalent cation solution and collecting gelled particles; (c) a step for adding the particles collected in the step (b) to a poly-L-ornithine solution A, stirring the mixture, and then collecting particles; (d) a step for adding the particles collected in the step (c) to a sodium alginate solution B, stirring the mixture, and then collecting particles; and (e) a step for adding the particles collected in the step (d) to a sodium citrate solution, stirring the mixture, and then collecting particles.
Provided is an improved method for producing a pancreatic islet-containing capsule. This method for producing a pancreatic islet-containing capsule includes: (a) a step for preparing a sodium alginate solution A containing pancreatic islands at a concentration of at least 10,000 IEQ/mL; (b) a step for dropping the sodium alginate solution into a divalent cation solution and collecting gelled particles; (c) a step for adding the particles collected in the step (b) to a poly-L-ornithine solution A, stirring the mixture, and then collecting particles; (d) a step for adding the particles collected in the step (c) to a sodium alginate solution B, stirring the mixture, and then collecting particles; and (e) a step for adding the particles collected in the step (d) to a sodium citrate solution, stirring the mixture, and then collecting particles.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
The present invention addresses the problem of providing a hematopoietic-cell storage solution or the like: with which it is possible to effectively suppress a reduction in cell survival rate, cell aggregation, and cell adhesion to a storage vessel that occur when hematopoietic cells are stored in a trehalose-containing cell storage solution; and that is unlikely to adversely affect the ecology of a mammalian animal when administered to the living body of the mammalian animal. In the present invention, a solution that contains trehalose, a derivative thereof, or a salt of such substances and that has a pH of 4.5-7.2 is employed to store hematopoietic cells.
The purpose of the present invention is to provide an ointment preparation in which both separation over time and discoloration over time are suppressed. Both separation over time and discoloration over time are suppressed in: a topical composition containing (A) 30-60 weight % of zinc chloride, a specific (B) inorganic powder and a specific (C) additive, and (D) a solvent; and a topical composition containing (A) 30-60 weight % of zinc chloride, a specific (B) inorganic powder, and (D) a solvent.
An antiseptic composition with a more extended applicable range by further enhancing the efficacy of olanexidine gluconate, which has been used as a highly safe dermal bactericidal disinfectant, and extending antibacterial spectrum. The antiseptic composition includes and has a more extended bactericidal spectrum than conventional disinfectants.
The present invention provides a medical tube position confirmation system for confirming the position of a medical tube for transluminally supplying nutrition into a body, an end part of the medical tube being implanted in the stomach, the medical tube position confirmation system being characterized by including: a light guide body that is configured to guide light incident from an incidence end part and to emit the light from an emission end part and is configured to be insertable into the medical tube such that the emission end part is disposed inside the stomach; a light source that is optically connected to the incidence end part of the light guide body and emits light having a wavelength to be transmitted through a living body; and a control unit for controlling the intensity of light emitted by the light source, wherein the control unit controls the intensity of the light emitted by the light source so as to be within a patient-specific intensity range of a first intensity or more and less than a second intensity.
An object of the present invention is to provide a composition that can be used as a novel anti-inflammatory agent. An inflammation such as stomatitis, oral mucositis, gingivitis, or pneumonia can be ameliorated and/or prevented by using a composition comprising olanexidine or a pharmacologically acceptable salt thereof. The composition of the present invention preferably further comprises a poloxamer which is a block copolymer consisting of a chain of polyoxypropylene (POP) and two chains of polyoxyethylene (POE) flanking the POP.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A drug solution container comprising: at least two accommodating chambers for accommodating drug solutions; a weak seal portion that partitions the accommodating chambers, it being possible to detach the weak seal portion by applying pressure to the accommodating chambers from outside; a flap portion that is provided with a hanging hole and is folded toward the accommodating chambers; and a seal portion that covers the hanging hole and is fixed to the accommodating chambers in a state in which the flap portion is folded toward the accommodating chambers. The seal portion has an opening portion that is configured so as to cover at least part of the hanging hole and so that the hanging hole can be opened without being separated from the seal portion when the drug solution container is used.
A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
The present invention provides an infusion preparation that is inhibited from generation of unwanted insoluble matter after mixing of two liquids of the infusion preparation in long-term storage. More specifically, the present invention provides an infusion preparation comprising two chambers separated by a communicably openable partition, a first chamber containing a first-chamber infusion comprising a fat emulsion and further comprising at least one member selected from the group consisting of amino acids that have a buffer action, divalent organic acids, and trivalent organic acids, a second chamber containing a second-chamber infusion comprising an amino acid and at least calcium as an electrolyte, wherein a total concentration of the amino acids that have a buffer action, divalent organic acids, and trivalent organic acids in the first-chamber infusion is 0.15 to 0.5 g/L, and a mixture of the first- and second-chamber infusions has a pH of 6.53 or less as measured 48 hours after the partition is communicably opened.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations and other preparations for
destroying vermin, fungicides, herbicides; gauze for
dressings; dressings, medical; liquid bandages; dental
materials; chemical preparations for medical purposes;
chemical preparations for medical use, namely, transparent
gels for ensuring visual field in endoscopic examination and
treatment; chemical preparations for medical purposes for
use in the field of endoscopic examination and treatment. Medical apparatus and instruments, other than walking aids,
and crutches; endoscopy cameras for medical purposes;
medical apparatus and instruments for ensuring visual field
in endoscopic examination and treatment; medical articles
for ensuring visual field in endoscopic examination and
treatment; prosthetics or fillings materials, not for dental
use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, medical and veterinary preparations;
sanitary preparations for medical purposes; preparations for
destroying vermin; fungicides, herbicides; pharmaceutical
preparations for the treatment of malnutrition; amino acids
for medical purposes; amino acid preparations and substances
for medical purposes; injectable amino acid solutions for
medical purposes; infusion solution being pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, medical and veterinary preparations;
sanitary preparations for medical purposes; preparations for
destroying vermin; fungicides, herbicides; pharmaceutical
preparations and substances for kidney diseases;
pharmaceutical preparations for the treatment of
malnutrition; amino acids for medical purposes; amino acid
preparations and substances for medical purposes; injectable
amino acid solutions for medical purposes; infusion solution
being pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, medical and veterinary preparations;
sanitary preparations for medical purposes; preparations for
destroying vermin; fungicides, herbicides; pharmaceutical
preparations for the treatment of malnutrition; amino acids
for medical purposes; amino acid preparations and substances
for medical purposes; injectable amino acid solutions for
medical purposes; infusion solution being pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, medical and veterinary preparations;
sanitary preparations for medical purposes; dietetic food
and substances adapted for medical or veterinary use;
dietetic beverages adapted for medical purposes; food for
babies; lacteal flour for babies; beverages for babies;
dietary supplements for human beings and animals;
preparations for destroying vermin; fungicides, herbicides;
pharmaceutical preparations and substances for liver
diseases; pharmaceutical preparations for the treatment of
malnutrition; amino acids for medical purposes; amino acid
preparations and substances for medical purposes; injectable
amino acid solutions for medical purposes; infusion solution
being pharmaceuticals.
93.
TREHALOSE-CONTAINING LIQUID FOR MAMMALIAN CELL PRESERVATION
The present invention addresses the problem of providing a mammalian cell preservation liquid or the like that can effectively suppress reduction in the cell survival rate of mammalian cells occurring when the mammalian cells are preserved in liquid and suppress reduction in the self-replicative ability of mammal stem cells when the mammalian stem cells are preserved in liquid, and that is less likely to have an adverse influence on the life of a mammal when the mammalian cells are administered into the living body of the mammal. As a solution thereto, this mammalian cell preservation liquid that contains trehalose, a derivative thereof, or a salt thereof, and a hydrogen carbonate such as sodium hydrogen carbonate, as a pH adjusting agent, and that has a pH of 6.5-8.5, is used to preserve mammalian cells.
The present invention addresses the problem of providing a mammalian cell preservation liquid or the like that can effectively suppress reduction in the cell survival rate of mammalian cells occurring when the mammalian cells are preserved in liquid and suppress reduction in the self-replicative ability of mammal stem cells when the mammalian stem cells are preserved in liquid, and that is less likely to have an adverse influence on the life of a mammal when the mammalian cells are administered into the living body of the mammal. As a solution thereto, this mammalian cell preservation liquid that contains trehalose, a derivative thereof, or a salt thereof, and a hydrogen carbonate such as sodium hydrogen carbonate, as a pH adjusting agent, and that has a pH of 6.5-8.5, is used to preserve mammalian cells.
The purpose of the present invention is to provide a pharmaceutical composition that contains mesenchymal stem cells and that has an excellent therapeutic effect against various diseases, injuries, wounds, and bedsores. This invention relates to a pharmaceutical composition for treating a non-porcine animal, the pharmaceutical composition containing juvenile porcine-derived mesenchymal stem cells that produce at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A and VEGF-C.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
An objective of the present invention is to provide an infusion of improved subcutaneous diffusivity. Bicarbonate ions are included in the infusion for subcutaneous administration to improve the subcutaneous diffusivity of the infusion for subcutaneous administration. The infusion for subcutaneous administration is preferably in the form of Ringer's solution having a bicarbonate ion concentration of 10–50 mEq/L, a pH of 6.0–8.5, an osmolality ratio of 0.8–1.3 with respect to the osmolality of normal saline, and a dosage of 20–1500 ml/day, and can further contain sodium ions, potassium ions, calcium ions, magnesium ions, and citrate ions.
The present invention addresses the problem of providing a novel storage liquid for storing mammalian cells over a long period of time in a non-frozen state. Ascorbic acid and/or niacin are added to an isotonic liquid to give a storage liquid. Then the storage liquid is mixed with platelets and stored under shaking. Thus, deterioration in the functions of the platelets and a decrease in the survival rate thereof can be prevented for at least 10 days. When the aforesaid storage liquid is mixed with mesenchymal stem cells, megakaryocytes or T cells and stored in a non-frozen state, deterioration in the functions of these cells and a decrease in the survival rate thereof can be prevented for at least from several days to several ten days.
The present invention addresses the problem of providing a novel storage liquid for storing mammalian cells over a long period of time in a non-frozen state. Ascorbic acid and/or niacin are added to an isotonic liquid to give a storage liquid. Then the storage liquid is mixed with platelets and stored under shaking. Thus, deterioration in the functions of the platelets and a decrease in the survival rate thereof can be prevented for at least 10 days. When the aforesaid storage liquid is mixed with mesenchymal stem cells, megakaryocytes or T cells and stored in a non-frozen state, deterioration in the functions of these cells and a decrease in the survival rate thereof can be prevented for at least from several days to several ten days.
An object of the present invention is to provide stem cells having excellent proliferation ability and differentiation ability. The present invention relates to stem cells isolated from a neonatal pig, and a preparation method therefor.
The purpose of the present invention is to provide an adhesion prevention material capable of exhibiting excellent adhesion preventive effect. This adhesion prevention material concurrently uses: (A) a peptide (A-1) having an amino acid sequence-(X-Pro-Y)n-[wherein X represents an arbitrary defined amino acid, Pro represents proline, Y represents hydroxyproline or proline, and n is an integer between 1 and 10] and/or a peptide (A-2) having an amino acid sequence-(Pro-Y)m-[wherein Pro represents proline, Y represents hydroxyproline or proline, and m is an integer between 1-10]; and (B) a gelatin gel. This adhesion prevention material exhibits a dramatically enhanced adhesion preventive effect as compared with the case where the abovementioned components are used individually, and in particular, has a markedly superior effect against adhesion of tendons.
C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
C07K 14/79 - Transferrins, e.g. lactoferrins, ovotransferrins
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 1/00 - General processes for the preparation of peptides
C07K 5/00 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof
C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
A61P 41/00 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
